A Study With Pentasa in Patients With Active Crohn's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Crohn´s Disease
Interventions
DRUG

Pentasa

6 g/day orally, 2 g in the morning and 4 g in the evening

DRUG

Placebo

6 g/day orally, 2 g in the morning and 4 g in the evening

Trial Locations (15)

Unknown

San Diego Clinical Trials, San Diego

Clinical Research of West Florida, Clearwater

Atlanta Gastroenterology Specialists, John's Creek

Center for Digestive and Liver Disease, Inc, Mexico

Wake Research Associates, Raleigh

Consultants for Clinical Research Inc., Cincinnati

Hartwell Research Group, LLC, Anderson

CHC Saint Joseph, Liège

Herlev University Hospital, Copenhagen

Investigational Site, Lille

Investigational Site, Berlin

Internist Gastroenterologie, Evangelisches Krankenhaus Kalk Akad. Lehrkrankenhaus für die Universität Köln, Cologne

Gemeinschaftspraxis, Leipzig

Lunds Lasaret, Lund

Addenbrookes Hospital, Cambridge

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY